THERAVIA

Norgine Expands Rare Disease Portfolio with Strategic Acquisition of Theravia

- Norgine has entered a definitive agreement to acquire Theravia from Mérieux Equity Partners, adding key rare disease treatments SIKLOS® for sickle cell disease and ORPHACOL® for genetic bile disorders to its portfolio. - The acquisition aligns with Norgine's growth strategy, creating a European-based rare disease champion with six core products that will serve as key growth drivers in the medium-to-long term. - This transaction follows Norgine's recent deals with Fennec Pharma for PEDMARQSI® and X4 Pharma for mavorixafor, establishing the company as a partner of choice for commercializing rare and specialty pharmaceuticals in Europe.